Verzoni E - Search Results

1

Does Dose Modification Affect Efficacy of First-Line Pazopanib in Metastatic Renal Cell Carcinoma?

Grassi P, Verzoni E, Ratta R, Porcu L, Prisciandaro M, Mennitto A, Calareso G, de Braud F, Procopio G. Grassi P, et al. Among authors: verzoni e. Drugs R D. 2017 Sep;17(3):461-467. doi: 10.1007/s40268-017-0203-y. Drugs R D. 2017. PMID: 28801802 Free PMC article.

2

Neuroendocrine tumors of the larynx: a clinical report and literature review.

Procopio G, Ricotta R, Fusi A, Celio L, De Dosso S, Catena L, Ferrari L, Quattrone P, Verzoni E, Bajetta E. Procopio G, et al. Among authors: verzoni e. Tumori. 2006 Jan-Feb;92(1):72-5. Tumori. 2006. PMID: 16683387

3

Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours?

Bajetta E, Catena L, Procopio G, De Dosso S, Bichisao E, Ferrari L, Martinetti A, Platania M, Verzoni E, Formisano B, Bajetta R. Bajetta E, et al. Among authors: verzoni e. Cancer Chemother Pharmacol. 2007 Apr;59(5):637-42. doi: 10.1007/s00280-006-0306-6. Epub 2006 Aug 26. Cancer Chemother Pharmacol. 2007. PMID: 16937105

4

Renal cell cancer and sorafenib: skin toxicity and treatment outcome.

Bajetta E, Procopio G, Verzoni E, Catena L, De Dosso S, Platania M, Gevorgyan A. Bajetta E, et al. Among authors: verzoni e. Tumori. 2007 Mar-Apr;93(2):201-3. doi: 10.1177/030089160709300216. Tumori. 2007. PMID: 17557570

5

Pulmonary carcinoid tumours: indolent but not benign.

De Dosso S, Bajetta E, Procopio G, Cortinovis D, Buzzoni R, Catena L, Platania M, Verzoni E. De Dosso S, et al. Among authors: verzoni e. Oncology. 2007;73(3-4):162-8. doi: 10.1159/000127382. Epub 2008 Apr 16. Oncology. 2007. PMID: 18418008

6

Safety and activity of sorafenib in different histotypes of advanced renal cell carcinoma.

Procopio G, Verzoni E, Gevorgyan A, Mancin M, Pusceddu S, Catena L, Platania M, Guadalupi V, Martinetti A, Bajetta E. Procopio G, et al. Among authors: verzoni e. Oncology. 2007;73(3-4):204-9. doi: 10.1159/000127387. Epub 2008 Apr 16. Oncology. 2007. PMID: 18418013

7

Feasibility and activity for sequencing targeted therapies for the treatment of advanced renal cell carcinoma.

Procopio G, Verzoni E, Bajetta E. Procopio G, et al. Among authors: verzoni e. Med Oncol. 2010 Dec;27(4):1267-8. doi: 10.1007/s12032-009-9371-0. Epub 2009 Dec 2. Med Oncol. 2010. PMID: 19957113 No abstract available.

8

Is it possible to optimize the use of targeted therapies in the treatment of renal cell carcinoma?

Procopio G, Verzoni E, Guadalupi V, Iacovelli R, Bajetta E. Procopio G, et al. Among authors: verzoni e. Tumori. 2010 Sep-Oct;96(5):794-5. doi: 10.1177/030089161009600528. Tumori. 2010. PMID: 21302633 No abstract available.

9

Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: the ROSORC trial.

Procopio G, Verzoni E, Bracarda S, Ricci S, Sacco C, Ridolfi L, Porta C, Miceli R, Zilembo N, Bajetta E. Procopio G, et al. Among authors: verzoni e. Br J Cancer. 2011 Apr 12;104(8):1256-61. doi: 10.1038/bjc.2011.103. Epub 2011 Mar 29. Br J Cancer. 2011. PMID: 21448165 Free PMC article. Clinical Trial.

10

Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma (RCC): an Italian multicentre retrospective analysis of 189 patient cases.

Porta C, Procopio G, Cartenì G, Sabbatini R, Bearz A, Chiappino I, Ruggeri EM, Re GL, Ricotta R, Zustovich F, Landi L, Calcagno A, Imarisio I, Verzoni E, Rizzo M, Paglino C, Guadalupi V, Bajetta E. Porta C, et al. Among authors: verzoni e. BJU Int. 2011 Oct;108(8 Pt 2):E250-7. doi: 10.1111/j.1464-410X.2011.10186.x. Epub 2011 May 23. BJU Int. 2011. PMID: 21599821

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

166 results

Search Page

Filters